Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Dose Doxycycline for Tick-borne Relapsing Fever Prophylaxis
NCT06045481Not yet recruiting
- Sponsor
- Israel Defense Forces Medical Corps
- Start
- Aug 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of doxycycline in Tick-borne relapsing fever (TBRF) (2 arms), sponsored by Israel Defense Forces Medical Corps. Primary endpoint: Preventing Tick borne recurrent fever at 3 weeks. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
doxycycline
03
Conditions
Tick-borne relapsing fever (TBRF)
Beyond the preview
Go deeper on NCT06045481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045481.